BTIG upgrades SOPHiA GENETICS price target to $8 on strong regional growth and leadership transition
BTIG raises valuation target for SOPHiA GENETICS SA to $8 while maintaining a Buy rating, citing confidence in incoming management and robust quarter-four results
On 15 April 2026, BTIG increased its price target on SOPHiA GENETICS SA (NASDAQ:SOPH) from $7 to $8, retaining its Buy rating for the healthcare technology firm. The analyst decision follows investor engagements with key executives, including President and incoming CEO Ross Muken, CFO George Cardoza, and Head of Strategy Kellen Sanger. BTIG noted that management's sentiment regarding the incoming leadership team has reinforced confidence across the business.
The upgrade comes after SOPHiA GENETICS reported fourth-quarter 2025 earnings per share of (28c), a slight widening of the loss compared to the (23c) recorded in the same period the previous year. Despite the negative earnings, revenue reached $21.7 million, marking a significant increase from $17.7 million in the prior year. This performance reflects a full-year 2025 revenue growth of 19%, driven by strong momentum in specific geographic markets.
Regional expansion has been the primary catalyst for the company's recent financial performance. North America revenue grew by 45% year-over-year, while the Asia Pacific region recorded 32% growth. CEO Jurgi Camblong highlighted that the company finished 2025 with strong momentum, noting that Q4 revenue specifically rose by 22%. These figures underpin the company's outlook for fiscal 2026, where it expects revenue to fall between $92 million and $94 million.
The 2026 revenue forecast of $92 million to $94 million significantly exceeds market consensus estimates of $76.47 million, representing an anticipated growth rate of between 20% and 22% year-on-year. However, investors should note that the company projects adjusted EBITDA to remain negative, with a range between ($29 million) and ($32 million) for the coming fiscal year. This outlook aligns with the company's current classification as a growth-stage enterprise specialising in cloud-based software tools for clinical data analysis.
SOPHiA GENETICS continues to be recognised as one of the eight best healthcare AI stocks to buy according to analysts, reflecting its strategic position in the sector. The firm provides cloud-based software designed to assist healthcare providers in analysing complex clinical data and generating insights across multiple diagnostic platforms. While the company acknowledges the potential of its investment thesis, BTIG maintains that certain other AI stocks may currently offer greater upside potential with reduced downside risk.
The broader market context has seen significant institutional activity in technology sectors, with heavy buying observed in shares of companies like NVIDIA and Amazon following strong earnings reports. While these broader trends highlight the appetite for technology, the specific upgrade for SOPHiA GENETICS is grounded in its own operational metrics and the strategic confidence of its leadership team. The firm's ability to deliver on its 2026 revenue targets will be critical in sustaining the positive sentiment noted by BTIG.
